about
Pharmacogenetics of antipsychotics.The AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism.No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain.Physicians' opinions following pharmacogenetic testing for psychotropic medication.Role of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gain.A hypothesis-driven association study of 28 nuclear-encoded mitochondrial genes with antipsychotic-induced weight gain in schizophrenia.Pharmacogenetics of obsessive-compulsive disorders.Genetics and personalized medicine in antidepressant treatment.Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic.Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: an update and implications for clinicians.Genetic variation in CYP3A43 is associated with response to antipsychotic medication.Cortical surface-based threshold-free cluster enhancement and cortexwise mediation.Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes.Exploratory study on association of genetic variation in TBC1D1 with antipsychotic-induced weight gain.Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients.Quantitative historical analysis uncovers a single dimension of complexity that structures global variation in human social organization.Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain.Investigation of melanocortin system gene variants in antipsychotic-induced weight gain.Fat mass- and obesity-associated (FTO) gene and antipsychotic-induced weight gain: an association study.Association Study of Serotonin 3 Receptor Subunit Gene Variants in Antipsychotic-Induced Weight Gain.Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain.Association of orexin receptor polymorphisms with antipsychotic-induced weight gain.Association study of GABAA α2 receptor subunit gene variants in antipsychotic-associated weight gain.The influence of MIR137 on white matter fractional anisotropy and cortical surface area in individuals with familial risk for psychosis.Association study between the neurexin-1 gene and tardive dyskinesia.Association of Dystrobrevin-Binding Protein 1 Polymorphisms with Sustained Attention and Set-Shifting in Schizophrenia Patients.Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication.[Clinical and sociodemographic Differences Between Patients with and without Migration Background in a Psychiatric Outpatient Service].From pharmacogenetics to imaging pharmacogenetics: elucidating mechanisms of antidepressant response.F1. GENOME-WIDE ASSOCIATION STUDIES SUGGESTED ASSOCIATION BETWEEN DGKB AND ANTIPSYCHOTIC INDUCED WEIGHT GAIN IN EUROPEANS AND AFRICAN AMERICANS.Reply to Tosh et al.: Quantitative analyses of cultural evolution require engagement with historical and archaeological researchMultimodal neuroimaging measures and intelligence influence pedophile child sexual offense behavior274. MIR137 Influences White Matter Fractional Anisotropy and Cortical Surface Area in Individuals with High Genetic Risk for PsychosisAlcohol and Dementia - What is the Link? A Systematic Review[The Influence of Residence Status on Psychiatric Symptom Load of Asylum Seekers in Germany]
P50
Q33836837-445F3E7D-5C09-4DBF-BC50-1F9392548B1BQ34330986-7A278CB2-D32F-46A6-817C-BB8F48971760Q35192874-980AD273-B04C-4452-8C88-9F541AB9DEF3Q35753028-644A9D2F-AAF1-4A74-A65B-9D012D841492Q36441507-2F9508C5-EC3E-4D9B-949A-EC70AC68F097Q37705728-59033D07-F54E-45B5-9DFD-A1F288827B09Q37969219-6B8B673E-F79E-4374-86B5-59FF93ACDD05Q38017264-3071F712-3219-450B-BD2C-E3DEE0F84224Q38154915-71E4315A-8050-4C6D-ACA4-C04D85BD64DEQ38236029-1C062788-2C9A-4F5B-989A-39437BBAD9DCQ38242595-41F64645-8564-463B-9C40-E9A2F21465A4Q38895053-F58E05C4-7D91-4A70-8957-62A799F9A01AQ38983579-D3A2F9B7-6B12-474F-BD96-FACBB5F2704AQ39064271-06D9A876-85F9-48DA-AEC6-659982DE9918Q43943107-1BF7CCD4-5082-4E84-A607-E5E27E66CFF2Q45908927-3F4D0B49-6F9F-45AA-B394-1A8A3002AB28Q47178065-520EB4EA-9CFC-45A8-BBF3-92CD39388D82Q47178961-B3DDA77F-7D34-4BB2-84C4-54D79FD315F1Q47182191-13D68366-FC8B-441C-B866-B2156BC77BB8Q47185882-93F0253B-B554-49A7-89BD-BBEAC4D0C236Q47211764-016DFC00-89B8-4404-B98A-10C828B88E04Q47257590-FE4D2271-1608-41C0-BE36-E0AB448F35E6Q47355703-91AAF0D7-8D47-4B8F-8FD7-B6012F3E386FQ47418258-F284265D-DBEE-4BB1-90EC-3901F77ABFEEQ47610838-CEE71839-A93E-4970-B1F1-A9C6DE509CDCQ47818805-8FEE7D6E-8BDD-4AE2-8A43-7B154B385966Q50480578-A420BB5C-F9B9-4CDF-A41A-D64B58E375A2Q52804138-8B4C397E-B1A6-4F7D-A6FF-FCFB18F515A3Q52811212-C6D3F5D8-FA93-43DA-8A13-8DBD2B8213F4Q52837901-3D530900-7117-43B1-8408-1282BBC9ADFAQ55114719-C8C77091-A746-421A-93F3-959345632C51Q56614316-7E041298-9ED4-468B-B4AB-55A5A9FB6BEAQ56961307-F25CCDF9-0B47-46C5-BFD7-4470D80BF3DAQ56988894-874360A5-3C53-414C-92A3-75C64948E1F2Q89537269-1CDCEDC4-9964-46AD-85B6-1FCD6101280AQ90429957-D7FCC583-71F2-4312-9057-8076A2EF1F5C
P50
name
Eva J Brandl
@en
Eva J Brandl
@nl
type
label
Eva J Brandl
@en
Eva J Brandl
@nl
altLabel
Eva Brandl
@en
prefLabel
Eva J Brandl
@en
Eva J Brandl
@nl